These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 29574715)

  • 1. Treatment and outcome of adult-onset neuroblastoma.
    Suzuki M; Kushner BH; Kramer K; Basu EM; Roberts SS; Hammond WJ; LaQuaglia MP; Wolden SL; Cheung NV; Modak S
    Int J Cancer; 2018 Sep; 143(5):1249-1258. PubMed ID: 29574715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
    Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
    Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma.
    Cheung NK; Cheung IY; Kramer K; Modak S; Kuk D; Pandit-Taskar N; Chamberlain E; Ostrovnaya I; Kushner BH
    Int J Cancer; 2014 Nov; 135(9):2199-205. PubMed ID: 24644014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma.
    Cheung IY; Lo Piccolo MS; Kushner BH; Kramer K; Cheung NK
    J Clin Oncol; 2003 Mar; 21(6):1087-93. PubMed ID: 12637475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma.
    Cheung NK; Guo HF; Heller G; Cheung IY
    Clin Cancer Res; 2000 Jul; 6(7):2653-60. PubMed ID: 10914706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD
    Mueller I; Ehlert K; Endres S; Pill L; Siebert N; Kietz S; Brock P; Garaventa A; Valteau-Couanet D; Janzek E; Hosten N; Zinke A; Barthlen W; Varol E; Loibner H; Ladenstein R; Lode HN
    MAbs; 2018 Jan; 10(1):55-61. PubMed ID: 29120699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.
    Cheung NK; Ostrovnaya I; Kuk D; Cheung IY
    J Clin Oncol; 2015 Mar; 33(7):755-63. PubMed ID: 25559819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
    Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
    Med Pediatr Oncol; 2001 Jan; 36(1):194-6. PubMed ID: 11464881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse.
    Raffaghello L; Marimpietri D; Pagnan G; Pastorino F; Cosimo E; Brignole C; Ponzoni M; Montaldo PG
    Cancer Lett; 2003 Jul; 197(1-2):205-9. PubMed ID: 12880983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study.
    Kushner BH; Kramer K; Modak S; Cheung NK
    J Clin Oncol; 2011 Mar; 29(9):1168-74. PubMed ID: 21343563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.
    Cheung NK; Kushner BH; Cheung IY; Kramer K; Canete A; Gerald W; Bonilla MA; Finn R; Yeh SJ; Larson SM
    J Clin Oncol; 1998 Sep; 16(9):3053-60. PubMed ID: 9738575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-GD2 immunotherapy for neuroblastoma.
    Sait S; Modak S
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):889-904. PubMed ID: 28780888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy.
    Gorostegui M; Muñoz JP; Perez-Jaume S; Simao-Rafael M; Larrosa C; Garraus M; Salvador N; Lavarino C; Krauel L; Mañe S; Castañeda A; Mora J
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.
    Cheung NK; Cheung IY; Kushner BH; Ostrovnaya I; Chamberlain E; Kramer K; Modak S
    J Clin Oncol; 2012 Sep; 30(26):3264-70. PubMed ID: 22869886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
    Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
    Front Immunol; 2021; 12():690467. PubMed ID: 34367149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma.
    Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
    Clin Cancer Res; 1998 Sep; 4(9):2135-9. PubMed ID: 9748131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G
    Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Kramer K; Modak S; Yataghene K; Cheung NK
    Oncoimmunology; 2015 Jul; 4(7):e1016704. PubMed ID: 26140243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
    Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
    Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial.
    Kushner BH; Cheung IY; Modak S; Basu EM; Roberts SS; Cheung NK
    JAMA Oncol; 2018 Dec; 4(12):1729-1735. PubMed ID: 30326045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody.
    Kushner BH; Modak S; Basu EM; Roberts SS; Kramer K; Cheung NK
    Cancer; 2013 Aug; 119(15):2789-95. PubMed ID: 23633099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.